JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

Clarus plans to list this patent in FDA’s Orange Book, which would bring the total number of Orange Book-listed patents covering JATENZO to eight

NORTHBROOK, Ill., May 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent for claims that cover Clarus’ oral testosterone replacement product, JATENZO (testosterone undecanoate).

Patent No. 11,331,325 entitled “Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same” covers Clarus’ commercialized product, JATENZO. The new patent will expire in January 2027.

“This new patent further reinforces our already impressive intellectual property portfolio for JATENZO,” said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. “We believe that having eight patents listed in FDA’s Orange Book underscores our multi-pronged strategy for success in the marketplace by protecting this important asset.”

About Male Hypogonadism Male hypogonadism is a condition that results when the testes do not produce enough testosterone. Symptoms associated with male hypogonadism can include depression, decreased sex drive, decreased muscle mass, and decreased bone density, among others. An estimated 20 million men in the United States have hypogonadism, with approximately six million patients diagnosed. Treatments for male hypogonadism may include testosterone replacement therapy.

About Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus’ first commercial product is JATENZO® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).

Clarus Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements” for purposes of the federal securities laws. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Clarus’ forward-looking statements in this press release include, but are not limited to, statements regarding listing the new patent in the FDA’s Orange Book, the timing of the expiration of the new patent and the effect of the new patent on the JATENZO patent portfolio. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that Clarus has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Clarus’ control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with pharmaceutical development, risks associated with Clarus’ financial position, and those factors described under the heading “Risk Factors” in Clarus’ annual report on 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the SEC) on March 31, 2022, and those that are included in any of Clarus’ future filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Clarus’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic and there may be additional risks that Clarus considers immaterial, or which are unknown. It is not possible to predict or identify all such risks. Clarus’ forward-looking statements only speak as of the date they are made, and Clarus does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

JATENZO® is a registered trademark of Clarus Therapeutics Holdings, Inc.

Clarus Contact: Kara Stancell Vice President, Investor Relations & Corporate Communications kstancell@clarustherapeutics.com (847) 562-4300 x 206

Indication JATENZO® (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.

Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

Limitation of use Safety and efficacy of JATENZO in males less than 18 years old have not been established.

WARNING: INCREASES IN BLOOD PRESSURE

JATENZO can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death.

Before initiating JATENZO, consider the patient’s baseline cardiovascular risk and ensure blood pressure is adequately controlled.

Periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension and re-evaluate whether the benefits of JATENZO outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease on treatment.

Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

CONTRAINDICATIONS JATENZO is contraindicated in men with breast cancer or known or suspected prostate cancer. JATENZO is contraindicated in women who are pregnant as testosterone may cause fetal harm.

Check hematocrit prior to initiation and every 3 months while a patient is on JATENZO and if hematocrit becomes elevated, stop JATENZO until hematocrit decreases to an acceptable level. If hematocrit increases after JATENZO is restarted, stop permanently.

Monitor patients with benign prostatic hyperplasia (BPH) treated with androgens due to an increased risk for worsening signs and symptoms of BPH.

Venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone replacement products like JATENZO. Evaluate patients with signs or symptoms consistent with DVT or PE and, if a VTE is suspected, discontinue JATENZO and initiate appropriate workup and management.

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids.

Large doses of androgens can suppress spermatogenesis by feedback inhibition of pituitary FSH. Inform patients of this risk before prescribing JATENZO.

Prolonged use of high doses of methyltestosterone has been associated with serious hepatic adverse events. JATENZO is not known to cause these adverse events; however, patients should be instructed to report any signs of hepatic dysfunction and JATENZO should be discontinued while the cause is evaluated.

Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.

Gynecomastia may develop and persist in patients being treated for hypogonadism.

Sleep apnea may occur in some patients, especially those with risk factors such as obesity or chronic lung disease.

Changes in the serum lipid profile may require dose adjustment of lipid-lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy.

Use JATENZO with caution in cancer patients at risk of hypercalcemia. Monitor serum calcium concentration regularly during treatment with JATENZO in these patients.

Androgens, including JATENZO, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Depression and suicidal ideation have been reported in patients treated with JATENZO in clinical trials.

ADVERSE EVENTS The most common adverse events of JATENZO (incidence ≥2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

These are not all of the risks associated with JATENZO. For more information, click here for full Prescribing Information, including BOXED WARNING on increases in blood pressure. You can also obtain information regarding JATENZO at www.jatenzo.com.

© 2022 Clarus Therapeutics, Inc. All rights reserved.

What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.

Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down 53% as of 12:24 p.m. ET Friday, according to data from S&P Global Market Intelligence, following the release of disappointing results from a pivotal melanoma drug trial released Thursday evening. Iovance had already reported solid results for melanoma treatment Lifileucel in the middle of last year, ultimately finding a response rate of 36%. This follow-on study of cancer patients with advanced melanoma who had shown improvement after previously receiving and responding to anti-PD-1/L1 therapies isn't as encouraging, with an objective response rate of only 29%.

The company's protein-based shot has been authorized or approved in several other countries, including the U.K. and Singapore.

Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.

The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”

The White House on Thursday announced more steps to make the antiviral treatment Paxlovid more accessible across the U.S., cautioning that COVID-19 cases are likely to continue to climb over the summer travel season.

Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.

Shares of Avadel Pharmaceuticals PLC tumbled 21.6% in premarket trading on Thursday after the company said in a securities filing that the Food and Drug Administration requested additional information for its experimental narcolepsy drug. Avadel said it now expects to get a FDA decision on the drug, FT218, by June of next year. The company's stock is down 58.1% this year, while the S&P 500 has declined 16.5%.

The dominant coronavirus strain in the U.S. spreads faster than its predecessors, is adept at escaping immunity and might cause more serious disease.

An investment climate that's suddenly turned chilly may leave promising companies out in the cold.

Wearables can provide key data to help individuals bolster their mental health, Whoop founder and CEO Will Ahmed recently told Yahoo Finance.

A Tokyo court began hearings Thursday in a lawsuit seeking nearly $5 million in damages for six people who were children in Fukushima at the time of its 2011 nuclear power plant disaster and later developed thyroid cancer. The plaintiffs are suing the operator of the nuclear plant, saying radiation released in the accident caused their illnesses. It is the first group lawsuit filed by Fukushima residents over health problems allegedly linked to the disaster, their lawyers say.

The Centers for Disease Control and Prevention have identified nine cases of Monkeypox in seven states. Dr. Mike joins "Good Day Philadelphia" to discuss.

While many of us optimistically hoped that the coronavirus would be a distant memory at this point, that is hardly the reality. We entered 2022 in one of the worst surges throughout the entire pandemic, with the Omicron variant creating record high infection numbers across the U.S. And despite COVID numbers falling substantially throughout February and March, they are back on the rise again. In the last week, the U.S. has reported an average of almost 110,000 new infections every day, according

With Memorial Day near, many Americans are looking to fire up the grill. Just make sure you do it safely. Here are tips for cooking safely.

One of Greater Cincinnati's largest public companies will help other diagnostic businesses develop monkeypox tests.

Orange County student with brain cancer granted dying wish to graduate high school

CVS Health and Walmart will stop filling prescriptions for controlled substances ordered by clinicians working for Cerebral Inc. and Done Health, the broadest curbs yet by major pharmacies against the telehealth companies following scrutiny of their prescription practices. Cerebral had earlier disclosed the change to The Wall Street Journal.

The number of new coronavirus cases and deaths are still falling globally after peaking in January, the World Health Organization said. COVID-19 cases rose in only two regions of the world: the Americas and the Western Pacific. WHO said it is tracking all omicron subvariants as “variants of concern.”